Blockade of EMAP II protects cardiac function after chronic myocardial infarction by inducing angiogenesis.

[1]  B. Gersh,et al.  Cell therapy for human ischemic heart diseases: critical review and summary of the clinical experiences. , 2014, Journal of molecular and cellular cardiology.

[2]  Charles E. Murry,et al.  Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate Non-Human Primate Hearts , 2014, Nature.

[3]  M. Rota,et al.  Human heart failure: is cell therapy a valid option? , 2014, Biochemical pharmacology.

[4]  J. Marín-García,et al.  Myocardial regeneration of the failing heart , 2013, Heart Failure Reviews.

[5]  W. R. MacLellan,et al.  Regeneration potential of adult cardiac myocytes , 2013, Cell Research.

[6]  J. Loscalzo,et al.  Cardiomyogenesis in the Aging and Failing Human Heart , 2012, Circulation.

[7]  C. Murry,et al.  Heart regeneration , 2011, Nature.

[8]  P. Goichberg,et al.  Cardiomyogenesis in the Adult Human Heart , 2010, Circulation research.

[9]  N. Awasthi,et al.  EMAP II-Based Antiangiogenic-Antiendothelial In Vivo Combination Therapy of Pancreatic Cancer , 2010, Annals of Surgical Oncology.

[10]  N. Awasthi,et al.  Antitumor effects of EMAP II against pancreatic cancer through inhibition of fibronectin-dependent proliferation , 2010, Cancer biology & therapy.

[11]  R. Bellazzi,et al.  TWEAK is a positive regulator of cardiomyocyte proliferation. , 2010, Cardiovascular research.

[12]  I. Kron,et al.  Stem cell therapy for ischemic heart disease: where are we? , 2009, Current opinion in organ transplantation.

[13]  K. Nakayama,et al.  Cardiomyocyte proliferation and protection against post-myocardial infarction heart failure by cyclin D1 and Skp2 ubiquitin ligase. , 2008, Cardiovascular research.

[14]  Christine L. Mummery,et al.  Embryonic Stem (es) Cells from Mice and Primates Can Differentiate into Any Cell Type in the Adult Body Stem Cells in Fetal and Adult Hearts Stem-cell-based Therapy and Lessons from the Heart Insight Review , 2022 .

[15]  A. Kornelyuk,et al.  Antitumor effect of endothelial monocyte-activating polypeptide-II on human prostate adenocarcinoma in mouse xenograft model. , 2007, Experimental oncology.

[16]  Lila R Collins,et al.  Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.

[17]  W. R. MacLellan,et al.  Cardiac myocyte cell cycle control in development, disease, and regeneration. , 2007, Physiological reviews.

[18]  S. Epstein,et al.  Cell-based therapy for myocardial ischemia and infarction: pathophysiological mechanisms. , 2007, Annual review of pathology.

[19]  M. Schwarz,et al.  In vivo therapy of local tumor progression by targeting vascular endothelium with EMAP-II. , 2004, The Journal of surgical research.

[20]  M. Schwarz,et al.  Epithelial-mesenchymal interactions are linked to neovascularization. , 2004, American journal of respiratory cell and molecular biology.

[21]  D. Warburton,et al.  Endothelial Monocyte Activating Polypeptide II inhibits lung neovascularization and airway epithelial morphogenesis , 2000, Mechanisms of Development.

[22]  S. Libutti,et al.  Tumour necrosis factor receptor I (p55) is upregulated on endothelial cells by exposure to the tumour-derived cytokine endothelial monocyte- activating polypeptide II (EMAP-II). , 2000, Cytokine.

[23]  E. Kohn,et al.  Endothelial monocyte activating polypeptide II induces endothelial cell apoptosis and may inhibit tumor angiogenesis. , 2000, Microvascular research.

[24]  M. Schwarz,et al.  Temporo‐spatial distribution of endothelial‐monocyte activating polypeptide II, an anti‐angiogenic protein, in the mouse embryo , 2000, Developmental dynamics : an official publication of the American Association of Anatomists.

[25]  Jun Li,et al.  Endothelial-Monocyte Activating Polypeptide Ii, a Novel Antitumor Cytokine That Suppresses Primary and Metastatic Tumor Growth and Induces Apoptosis in Growing Endothelial Cells , 1999, The Journal of experimental medicine.

[26]  E. Topol,et al.  Reduction in myocardial infarct size by basic fibroblast growth factor following coronary occlusion in a canine model. , 1999, International journal of cardiology.

[27]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[28]  PieroAnversa,et al.  Ventricular Myocytes Are Not Terminally Differentiated in the Adult Mammalian Heart , 1998 .

[29]  R. Katori,et al.  Basic Fibroblast Growth Factor Increased Regional Myocardial Blood Flow and Limited Infarct Size of Acutely Infarcted Myocardium in Dogs , 1998, Angiology.

[30]  M. Zimmerman,et al.  A thyroid hormone analog stimulates angiogenesis in the post-infarcted rat heart. , 1998, Journal of molecular and cellular cardiology.

[31]  M. Franklin,et al.  Cardiomyocyte DNA synthesis and binucleation during murine development. , 1996, The American journal of physiology.

[32]  L. Brown,et al.  VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.

[33]  S. Libutti,et al.  Characterization of a novel tumor-derived cytokine. Endothelial-monocyte activating polypeptide II. , 1994, The Journal of biological chemistry.

[34]  Z. Darżynkiewicz,et al.  Myocyte cellular hyperplasia and myocyte cellular hypertrophy contribute to chronic ventricular remodeling in coronary artery narrowing-induced cardiomyopathy in rats. , 1994, Circulation research.

[35]  D. Stern,et al.  Endothelial-monocyte activating polypeptides (EMAPs): tumor derived mediators which activate the host inflammatory response. , 1993, Behring Institute Mitteilungen.

[36]  P. Familletti,et al.  Endothelial monocyte-activating polypeptide II. A novel tumor-derived polypeptide that activates host-response mechanisms. , 1992, The Journal of biological chemistry.

[37]  R. Zak.  Development and Proliferative Capacity of Cardiac Muscle Cells , 1974, Circulation research.

[38]  S. Vatner,et al.  Novel mechanisms for caspase inhibition protecting cardiac function with chronic pressure overload , 2012, Basic Research in Cardiology.

[39]  N. Awasthi,et al.  Endothelial monocyte activating polypeptide II interferes with VEGF-induced proangiogenic signaling , 2009, Laboratory Investigation.

[40]  N. Mochizuki,et al.  Expression of vascular endothelial growth factor in human myocardial infarction , 2005, Heart and Vessels.

[41]  B. Franc,et al.  Potential role for antiangiogenic proteins in the myocardial infarction repair process. , 2004, The Journal of surgical research.

[42]  D. Warburton,et al.  EMAP II: a modulator of neovascularization in the developing lung. , 1999, The American journal of physiology.